Use of gonadotropic releasing hormone agonists in hyperplastic syndrome in gynecology

Pashov A.I. Pashov, D.D. Matsakova, L.V. Volkova, V.V. Rachkovskaya, A. Turdieva
In: Russian Bulletin of Obstetrician-Gynecologist · 2025 · vol. 25(4) , pp. 51 · doi:10.17116/rosakush20252504151 · W4413223578
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review discusses the use of gonadotropin-releasing hormone agonists for hyperplastic gynecological conditions, detailing their mechanisms, benefits, side effects, and comparing them to alternative treatments.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

The paper reviews and discusses the use of gonadotropin-releasing hormone (GnRH) agonists for gynecologic “hyperplastic syndrome,” focusing on hyperplastic conditions such as uterine fibroids and related proliferative uterine disorders, outlining proposed mechanisms and clinical application contexts using published evidence. It synthesizes findings from prior studies and reviews on how GnRH agonists affect reproductive-endocrine signaling and can lead to changes in fibroid tissue characteristics, including shrinkage and molecular or receptor-related differences, while also noting practical considerations like treatment limitations. A stated caveat is that evidence is heterogeneous and many conclusions depend on study designs and the specific hyperplastic condition being addressed. Relevance to endometriosis: the manuscript includes and cites literature on GnRH-agonist use in endometriosis (e.g., Cochrane reviews and studies on bone mineral density, inflammatory changes, and add-back strategies), though its main focus is hyperplastic gynecologic conditions such as uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

This article raises current issues of the use of gonadotropin-releasing hormone (GnRH) in women suffering from hyperplastic conditions in gynecology. Such diseases include: uterine fibroids, endometriosis, endometrial hyperplasia, and endometrial cancer. The article pays special attention to the pathophysiological aspects of the action of this hormone, reveals its positive pharmacological properties, as well as negative, undesirable properties (side effects). Some etiopathogenetic aspects of the development of hyperplastic diseases in gynecology and the points of influence of GnRH on them are touched upon. This article examines the general principles of pharmacological treatment of hyperplastic processes with GnRH, and also compares it with other drugs: the advantages and disadvantages of treatment methods are described.
Full text 16,413 characters · extracted from oa-doi-fallback · click to expand
Сайт издательства «Медиа Сфера» содержит материалы, предназначенные исключительно для работников здравоохранения. Закрывая это сообщение, Вы подтверждаете, что являетесь дипломированным медицинским работником или студентом медицинского образовательного учреждения. Результаты поиска: 0 Применение агонистов гонадотропного рилизинг-гормона при гиперпластическом синдроме в гинекологии Журнал: Российский вестник акушера-гинеколога. 2025;25(4): 51‑58 Прочитано: 1279 раз Как цитировать: Литература / References: - Stamatiades GA, Kaiser UB. Gonadotropin regulation by pulsatile GnRH: Signaling and gene expression. Mol Cell Endocrinol. 2018;463:131-141. https://doi.org/10.1016/j.mce.2017.10.015 - Ciccone NA, Kaiser UB. The biology of gonadotroph regulation. Curr Opin Endocrinol Diabetes Obes. 2009;16:4:321-327. https://doi.org/10.1097/MED.0b013e32832d88fb - Kumar P, Sharma A. Gonadotropin-releasing hormone analogs: Understanding advantages and limitations. J Hum Reprod Sci. 2014;7:3:170-174. https://doi.org/10.4103/0974-1208.142476 - LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Gonadotropins. 2018. PMID: 31644163. - Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003;2003:4:CD001297. https://doi.org/10.1002/14651858.CD001297 - Министерство Здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. 2020. - Vigano P, Candiani M, Monno A, Giacomini E, Ver Cellini P, Somigliana E. Time to redefine endometriosis including its pro-fibrotic nature. Hum Reprod. 2018;33:3:347-352. - Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;5:261-275. https://doi.org/10.1038/nrendo.2013.255 - Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014;2014:3:CD009590. https://doi.org/10.1002/14651858.CD009590.pub2 - Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:3:400-412. https://doi.org/10.1093/humrep/det457 - Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertil Steril. 1990;54:3:419-427. https://doi.org/10.1016/s0015-0282(16)53755-8 - Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. Fertil Steril. 2017;107:3:555-565. https://doi.org/10.1016/j.fertnstert.2016.12.025 - Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol. 1999;93:51-58. - Mitwally MF, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause. 2002;9:4:236-241. https://doi.org/10.1097/00042192-200207000-00004 - Szendei G, Hernádi Z, Dévényi N, Csapó Z. Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment. Gynecol Endocrinol. 2005;21:2:93-100. https://doi.org/10.1080/09513590500107660 - Fernandez H, Agostini A, Baffet H, Chabbert-Buffet N, Descamps P, Estrade JP, Giraudet G, Hocke C, Salle B, Tremollieres F, Chapron C. Update on the management of endometriosis-associated pain in France. J Gynecol Obstet Hum Reprod. 2023;52:9:102664. https://doi.org/10.1016/j.jogoh.2023.102664 - Gallagher JS, Missmer SA, Hornstein MD, Laufer MR, Gordon CM, DiVasta AD. Long-term effects of gonadotropin-releasing hormone agonists and add-back in adolescent endometriosis. J Pediatr Adolesc Gynecol. 2018;31:4:376-381. https://doi.org/10.1016/j.jpag.2018.03.004 - Nirgianakis K, Bersinger NA, McKinnon B, Kostov P, Imboden S, Mueller MD. Regression of the inflammatory microenvironment of the peritoneal cavity in women with endometriosis by GnRHa treatment. Eur J Obstet Gynecol Reprod Biol. 2013;170:2:550-554. https://doi.org/10.1016/j.ejogrb.2013.08.010 - Olive DL. Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol. 2004;3:2:83-89. https://doi.org/10.2165/00024677-200403020-00003 - Loverro G, Carriero C, Rossi AC, Putignano G, Nicolardi V, Selvaggi L. A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III—IV endometriosis. Eur J Obstet Gynecol Reprod Biol. 2008;136:194-198. - Gong L, Zhang S, Han Y, Long Q, Zou S, Cao Y. Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial. J Clin Pharmacol. 2015;55:8:848-853. https://doi.org/10.1002/jcph.485 - Zheng Q, Mao H, Xu Y, Zhao J, Wei X, Liu P. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet. 2016;294:1:201-207. https://doi.org/10.1007/s00404-016-4085-y - Casteel CO, Singh G. Physiology, gonadotropin-releasing hormone. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022. PMID: 32644418. - Bedaiwy MA, Allaire C, Alfaraj S. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 2017;107:3:537-548. https://doi.org/10.1016/j.fertnstert.2016.12.024 - Lo SH. Tensin. Int J Biochem Cell Biol. 2004;36:1:31-34. https://doi.org/10.1016/s1357-2725(03)00171-7 - Chen H, Duncan IC, Bozorgchami H, Lo SH. Tensin1 and a previously undocumented family member, tensin2, positively regulate cell migration. Proc Natl Acad Sci USA. 2002;99:733-738. - Rahmawati E, Yang WV, Lei YP, Maurya PK, Chen HW, Tzeng CR. Gonadotropin-releasing hormone agonist induces downregulation of tensin 1 in women with endometriosis. Acta Obstet Gynecol Scand. 2019;98:2:222-231. https://doi.org/10.1111/aogs.13481 - Maggi R, Cariboni AM, Marelli MM, Moretti RM, Andrè V, Marzagalli M, Limonta P. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum Reprod Update. 2016;22:3:358-381. https://doi.org/10.1093/humupd/dmv059 - Hsu CC, Lin YS, Wang ST, Huang KE. Immunomodulation in women with endometriosis receiving GnRH agonist. Obstet Gynecol. 1997;89:6:993-998. https://doi.org/10.1016/s0029-7844(97)00145-2 - Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, Masuzaki H. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010;25:3:642-653. https://doi.org/10.1093/humrep/dep437 - Адамян Л.В., Арсланян К.Н., Харченко Э.И., Логинова О.Н. Современные направления в медикаментозном лечении эндометриоза. Проблемы репродукции. 2019;25:6:58-66. https://doi.org/10.17116/repro20192506158 - Министерство здравоохранения Российской Федерации. Клинические рекомендации. Миома матки. 2020. - Välimäki N, Kuisma H, Pasanen A, Heikinheimo O, Sjöberg J, Bützow R, Sarvilinna N, Heinonen H-R , Tolvanen J, Bramante S, Tanskanen T, Auvinen J, Uimari O, Alkodsi A, Lehtonen R, Kaasinen E, Palin K, Aaltonen LA. Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability. Elife. 2018;7:e37110. - Тихомиров А.Л. Агонисты гонадотропных рилизинг-гормонов в лечении миомы матки. РМЖ. Мать и дитя. 2010;18:4:188. - De La Cruz MS, Buchanan EM. Uterine fibroids: Diagnosis and treatment. Am Fam Physician. 2017;95:2:100-107. - Broekmans FJ. GnRH agonists and uterine leiomyomas. Hum Reprod. 1996;11 Suppl 3:3-25. https://doi.org/10.1093/humrep/11.suppl_3.3 - Vollenhoven BJ, Pearce P, Herington AC, Healy DL. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women. Clin Endocrinol (Oxf). 1994;40:537-544. - Kamath MS, Kalampokas EE, Kalampokas TE. Use of GnRH analogues pre-operatively for hysteroscopic resection of submucous fibroids: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;177:11-18. https://doi.org/10.1016/j.ejogrb.2014.03.009 - Zhu XQ, Shi YF, Cheng XD, Zhao CL, Wu YZ. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol. 2004;92:71-79. - Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Masuzaki H. Decreased expression of human heat shock protein 70 in the endometria and pathological lesions of women with adenomyosis and uterine myoma after GnRH agonist therapy. Eur J Obstet Gynecol Reprod Biol. 2015;187:6-13. https://doi.org/10.1016/j.ejogrb.2015.01.012 - Donnez J, Schrurs B, Gillerot S, Sandow J, Clerckx F. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril. 1989;51:6:947-950. https://doi.org/10.1016/s0015-0282(16)60723-9 - Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Böhling T, Koski TA, Launonen V, Sjöberg J, Taipale J, Vahteristo P, Aaltonen LA. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334:252-255. - Asano R, Asai-Sato M, Matsukuma S, Mizushima T, Taguri M, Yoshihara M, Inada M, Fukui A, Suzuki Y, Miyagi Y, Miyagi E. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities. Fertil Steril. 2019;111:178-185. - He C, Nelson W, Li H, Xu Y-D, Dai X-J, Wang Y-X, Ding Y-B, Li Y-P, Li T. Frequency of MED12 mutation in relation to tumor and patient’s clinical characteristics: a meta-analysis. Reprod Sci. 2022;29:357-365. - Nagai K, Asano R, Sekiguchi F, Asai-Sato M, Miyagi Y, Miyagi E. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 2023;228:2)207.e1-207.e9. https://doi.org/10.1016/j.ajog.2022.09.024 - Kim EH, Kim JY, Lee YH, Chong GO, Park JY, Hong DG. Comparison of estrogen receptor-α, progesterone receptor and calponin expression in gonadotrophin-releasing hormone agonist-sensitive and -resistant uterine fibroids. Obstet Gynecol Sci. 2014;57:2:144-150. https://doi.org/10.5468/ogs.2014.57.2.144 - Chung YJ, Chae B, Kwak SH, Song JY, Lee AW, Jo HH, Lew YO, Kim JH, Kim MR. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro. Int J Med Sci. 2014;11:3:276-281. https://doi.org/10.7150/ijms.7627 - Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy. BJOG. 2002;109:10:1097-1108. - Healy DL, Fraser HM, Lawson SL. Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist. Br Med J. 1984;209:6454:1267-1268. - Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2000;2:CD000547. Update in: Cochrane Database Syst Rev. 2001;2:CD000547. https://doi.org/10.1002/14651858.CD000547 - Imankulova B, Mereke A, Kamzaeva N, Ukybassova T. Comparing the use of uterine artery embolization to gonadotropin-releasing hormone agonists in shrinking fibroid size: A Pilot study in Kazakhstan. Cent Asian J Glob Health. 2015;4:1:232. https://doi.org/10.5195/cajgh.2015.232 - Министерство Здравоохранения Российской Федерации. Клинические рекомендации. Гиперплазия эндометрия. 2021. - Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zournatzi-Koiou V, Saravelos H, Kostopoulou E, Constantinidis T, Dinas K, Vavilis D, Lolis D, Bontis J. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas. 2004;48:2:125-132. - Agorastos T, Bontis J, Vakiani A, Vavilis D, Constantinidis T. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol. 1997;65:102-114. - Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatterjee J. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol. 2019;58:3:342-352. https://doi.org/10.1080/0284186X.2018.1540886 - Allison KH, Tenpenny E, Reed SD, Swisher EM, Garica RL. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. Appl Immunohistochem Mol Morphol. 2008;16:329-343. - Nagai N, Oshita T, Mukai K, Shiroyama Y, Shigemasa K, Ohama K. GnRH agonist inhibits human telomerase reverse transcriptase mRNA expression in endometrial cancer cells. Int J Mol Med. 2002;10:5:593-597. - Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27:1:e8. https://doi.org/10.3802/jgo.2016.27.e8 - Chen J, Cao D, Yang J, Yu M, Zhou H, Cheng N, Wang J, Zhang Y, Peng P, Shen K. Fertility-sparing treatment for endometrial cancer or atypical endometrial hyperplasia patients with obesity. Front Oncol. 2022;12:812346. https://doi.org/10.3389/fonc.2022.812346 - Chen JY, Cao DY, Zhou HM, Yu M, Yang JX, Wang JH, Zhang Y, Cheng NH, Peng P. GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy. Zhonghua Fu Chan Ke Za Zhi. 2021;56:8:561-568. Chinese. https://doi.org/10.3760/cma.j.cn112141-20210603-00298 - Пашов А.И., Сивова Е.Н., Волкова Л.В., Рачковская В.В. Опыт консервативного лечения атипической гиперплазии и эндометриальной карциномы: иммуногистохимические аспекты. Ш. 2023;4:155-160. - Пашов А.И., Сивова Е.Н., Метринский Я.Ю. Комбинированное применение агонистов гонадотропин-рилизинг-гормона и внутриматочной левоноргестрел-рилизинг-системы в лечении атипической гиперплазии эндометрия у женщин репродуктивного возраста. Ш. 2020;19:1:58-61. - Министерство Здравоохранения Российской Федерации. Клинические рекомендации. Рак тела матки и саркомы матки. 2021. - Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26:2:257-266. - Dinkelspiel HE, Wright JD, Lewin SN, Herzog TJ. Contemporary clinical management of endometrial cancer. Obstet Gynecol Int. 2013;2013:583891. - Пашов А.И., Цхай В.Б. Самостоятельная гормонотерапия начального рака эндометрия в репродуктивном возрасте. Acta Biomedica Scientifica. 2010;6-2:49-51. - Пашов А.И., Цхай В.Б., Сивова Е.Н. Комплексная гормонотерапия агонистами ГнРГ и внутриматочной левоноргестрел-рилизинг системой сложной атипической гиперплазии и аденокарциномы эндометрия: пилотное проспективное наблюдательное исследование. Злокачественные опухоли. 2012;2:1:15-17. - Нечушкина В.М., Коломиец Л.А., Кравец О.А., Морхов К.Ю., Новикова Е.Г., Новикова О.В., Тюляндина А.С., Ульрих Е.А., Феденко А.А., Хохлова С.В. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли. Практические рекомендации RUSSCO #3s2. 2022;12:260-275. - Петрожицкая А.А., Танделов Р.К., Зайцев Н.А., Морхов К.Ю. Органосохраняющее лечение атипической гиперплазии и рака эндометрия: современные тенденции. Злокачественные опухоли. 2023;13:2:5. Подтверждение e-mail На [email protected] отправлено письмо со ссылкой для подтверждения e-mail. Перейдите по ссылке из письма, чтобы завершить регистрацию на сайте. Подтверждение e-mail Мы используем файлы cооkies для улучшения работы сайта. Оставаясь на нашем сайте, вы соглашаетесь с условиями использования файлов cооkies. Чтобы ознакомиться с нашими Положениями о конфиденциальности и об использовании файлов cookie, нажмите здесь.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (57)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK